BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells

Mala Mani, Daniel E. Carrasco, Zhang Yunyu, Kohichi Takada, Moshe E. Gatt, Jui Dutta-Simmons, Hiroshi Ikeda, Felipe Diaz-Griffero, Victor Pena-Cruz, Monica Bertagnolli, Lois L. Myeroff, Sanford D. Markowitz, Kenneth C. Anderson, Daniel R. Carrasco

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Several components of the Wnt signaling cascade have been shown to function either as tumor suppressor proteins or as oncogenes in multiple human cancers, underscoring the relevance of this pathway in oncogenesis and the need for further investigation of Wnt signaling components as potential targets for cancer therapy. Here, using expression profiling analysis as well as in vitro and in vivo functional studies, we show that the Wnt pathway component BCL9 is a novel oncogene that is aberrantly expressed in human multiple myeloma as well as colon carcinoma. We show that BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases cell proliferation, migration, invasion, and the metastatic potential of tumor cells by promoting loss of epithelial and gain of mesenchymal-like phenotype. Most importantly, BCL9 knockdown significantly increased the survival of xenograft mouse models of cancer by reducing tumor load, metastasis, and host angiogenesis through down-regulation of c-Myc, cyclin D1, CD44, and vascular endothelial growth factor expression by tumor cells. Together, these findings suggest that deregulation of BCL9 is an important contributing factor to tumor progression. The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling.

Original languageEnglish (US)
Pages (from-to)7577-7586
Number of pages10
JournalCancer Research
Volume69
Issue number19
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Neoplasms
Oncogenes
Tumor Suppressor Proteins
Catenins
Wnt Signaling Pathway
Cyclin D1
Tumor Burden
Multiple Myeloma
Heterografts
Vascular Endothelial Growth Factor A
Cell Movement
Colon
Carcinogenesis
Down-Regulation
Cell Proliferation
Neoplasm Metastasis
Carcinoma
Phenotype
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mani, M., Carrasco, D. E., Yunyu, Z., Takada, K., Gatt, M. E., Dutta-Simmons, J., ... Carrasco, D. R. (2009). BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Research, 69(19), 7577-7586. https://doi.org/10.1158/0008-5472.CAN-09-0773

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. / Mani, Mala; Carrasco, Daniel E.; Yunyu, Zhang; Takada, Kohichi; Gatt, Moshe E.; Dutta-Simmons, Jui; Ikeda, Hiroshi; Diaz-Griffero, Felipe; Pena-Cruz, Victor; Bertagnolli, Monica; Myeroff, Lois L.; Markowitz, Sanford D.; Anderson, Kenneth C.; Carrasco, Daniel R.

In: Cancer Research, Vol. 69, No. 19, 01.10.2009, p. 7577-7586.

Research output: Contribution to journalArticle

Mani, M, Carrasco, DE, Yunyu, Z, Takada, K, Gatt, ME, Dutta-Simmons, J, Ikeda, H, Diaz-Griffero, F, Pena-Cruz, V, Bertagnolli, M, Myeroff, LL, Markowitz, SD, Anderson, KC & Carrasco, DR 2009, 'BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells', Cancer Research, vol. 69, no. 19, pp. 7577-7586. https://doi.org/10.1158/0008-5472.CAN-09-0773
Mani, Mala ; Carrasco, Daniel E. ; Yunyu, Zhang ; Takada, Kohichi ; Gatt, Moshe E. ; Dutta-Simmons, Jui ; Ikeda, Hiroshi ; Diaz-Griffero, Felipe ; Pena-Cruz, Victor ; Bertagnolli, Monica ; Myeroff, Lois L. ; Markowitz, Sanford D. ; Anderson, Kenneth C. ; Carrasco, Daniel R. / BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. In: Cancer Research. 2009 ; Vol. 69, No. 19. pp. 7577-7586.
@article{84d600aa544040ed97bee6d45173ca74,
title = "BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells",
abstract = "Several components of the Wnt signaling cascade have been shown to function either as tumor suppressor proteins or as oncogenes in multiple human cancers, underscoring the relevance of this pathway in oncogenesis and the need for further investigation of Wnt signaling components as potential targets for cancer therapy. Here, using expression profiling analysis as well as in vitro and in vivo functional studies, we show that the Wnt pathway component BCL9 is a novel oncogene that is aberrantly expressed in human multiple myeloma as well as colon carcinoma. We show that BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases cell proliferation, migration, invasion, and the metastatic potential of tumor cells by promoting loss of epithelial and gain of mesenchymal-like phenotype. Most importantly, BCL9 knockdown significantly increased the survival of xenograft mouse models of cancer by reducing tumor load, metastasis, and host angiogenesis through down-regulation of c-Myc, cyclin D1, CD44, and vascular endothelial growth factor expression by tumor cells. Together, these findings suggest that deregulation of BCL9 is an important contributing factor to tumor progression. The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling.",
author = "Mala Mani and Carrasco, {Daniel E.} and Zhang Yunyu and Kohichi Takada and Gatt, {Moshe E.} and Jui Dutta-Simmons and Hiroshi Ikeda and Felipe Diaz-Griffero and Victor Pena-Cruz and Monica Bertagnolli and Myeroff, {Lois L.} and Markowitz, {Sanford D.} and Anderson, {Kenneth C.} and Carrasco, {Daniel R.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-09-0773",
language = "English (US)",
volume = "69",
pages = "7577--7586",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells

AU - Mani, Mala

AU - Carrasco, Daniel E.

AU - Yunyu, Zhang

AU - Takada, Kohichi

AU - Gatt, Moshe E.

AU - Dutta-Simmons, Jui

AU - Ikeda, Hiroshi

AU - Diaz-Griffero, Felipe

AU - Pena-Cruz, Victor

AU - Bertagnolli, Monica

AU - Myeroff, Lois L.

AU - Markowitz, Sanford D.

AU - Anderson, Kenneth C.

AU - Carrasco, Daniel R.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Several components of the Wnt signaling cascade have been shown to function either as tumor suppressor proteins or as oncogenes in multiple human cancers, underscoring the relevance of this pathway in oncogenesis and the need for further investigation of Wnt signaling components as potential targets for cancer therapy. Here, using expression profiling analysis as well as in vitro and in vivo functional studies, we show that the Wnt pathway component BCL9 is a novel oncogene that is aberrantly expressed in human multiple myeloma as well as colon carcinoma. We show that BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases cell proliferation, migration, invasion, and the metastatic potential of tumor cells by promoting loss of epithelial and gain of mesenchymal-like phenotype. Most importantly, BCL9 knockdown significantly increased the survival of xenograft mouse models of cancer by reducing tumor load, metastasis, and host angiogenesis through down-regulation of c-Myc, cyclin D1, CD44, and vascular endothelial growth factor expression by tumor cells. Together, these findings suggest that deregulation of BCL9 is an important contributing factor to tumor progression. The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling.

AB - Several components of the Wnt signaling cascade have been shown to function either as tumor suppressor proteins or as oncogenes in multiple human cancers, underscoring the relevance of this pathway in oncogenesis and the need for further investigation of Wnt signaling components as potential targets for cancer therapy. Here, using expression profiling analysis as well as in vitro and in vivo functional studies, we show that the Wnt pathway component BCL9 is a novel oncogene that is aberrantly expressed in human multiple myeloma as well as colon carcinoma. We show that BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases cell proliferation, migration, invasion, and the metastatic potential of tumor cells by promoting loss of epithelial and gain of mesenchymal-like phenotype. Most importantly, BCL9 knockdown significantly increased the survival of xenograft mouse models of cancer by reducing tumor load, metastasis, and host angiogenesis through down-regulation of c-Myc, cyclin D1, CD44, and vascular endothelial growth factor expression by tumor cells. Together, these findings suggest that deregulation of BCL9 is an important contributing factor to tumor progression. The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling.

UR - http://www.scopus.com/inward/record.url?scp=70350225573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350225573&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-0773

DO - 10.1158/0008-5472.CAN-09-0773

M3 - Article

C2 - 19738061

AN - SCOPUS:70350225573

VL - 69

SP - 7577

EP - 7586

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 19

ER -